- Home
- TKC vs CNTA Comparison
TKC vs CNTA Comparison
Compare TKC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKC | CNTA |
|---|---|---|
| Founded | 1993 | 2020 |
| Country | Turkey | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TKC | CNTA |
|---|---|---|
| Price | $5.95 | $39.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $43.17 |
| AVG Volume (30 Days) | 678.4K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $31.20 | N/A |
| Revenue Next Year | $24.27 | N/A |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $10.95 |
| 52 Week High | $7.18 | $40.26 |
Technical Indicators
Market Signals| Indicator | TKC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 71.86 |
| Support Level | $5.89 | $39.36 |
| Resistance Level | $6.14 | $39.86 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | -0.05 | -0.33 |
| Stochastic Oscillator | 4.74 | 50.50 |
Price Performance
Historical ComparisonAbout TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.